Lyvgen Announces Phase 2 Clinical Collaboration with Bristol Myers Squibb to Evaluate LVGN7409 in Combination with Nivolumab in Non-Small Cell Lung Cancer Patients

LVGN7409 is a next generation CD40 agonistic antibody; Nivolumab is a PD-1 checkpoint inhibitor; docetaxel is an anti-tubulin chemotherapy agent Combination study to begin in 1st half 2023 SHANGHAI and SUZHOU, China, Nov. 27,...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials